Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexeo Therapeutics (LXEO) EBITDA: 2022-2023

Historic EBITDA for Lexeo Therapeutics (LXEO) over the last 1 years, with Dec 2023 value amounting to -$15.0 million.

  • Lexeo Therapeutics' EBITDA rose 1.47% to -$15.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$68.5 million, marking a year-over-year change of. This contributed to the annual value of -$98.4 million for FY2024, which is 48.26% down from last year.
  • According to the latest figures from Q4 2023, Lexeo Therapeutics' EBITDA is -$15.0 million, which was up 26.14% from -$20.3 million recorded in Q3 2023.
  • In the past 5 years, Lexeo Therapeutics' EBITDA registered a high of -$14.0 million during Q2 2023, and its lowest value of -$20.3 million during Q3 2023.
  • Its 2-year average for EBITDA is -$16.9 million, with a median of -$16.3 million in 2022.
  • Within the past 5 years, the most significant YoY rise in Lexeo Therapeutics' EBITDA was 1.47% (2023), while the steepest drop was 15.96% (2023).
  • Lexeo Therapeutics' EBITDA (Quarterly) stood at -$15.2 million in 2022, then climbed by 1.47% to -$15.0 million in 2023.
  • Its EBITDA was -$15.0 million in Q4 2023, compared to -$20.3 million in Q3 2023 and -$14.0 million in Q2 2023.